Profil
Andreas Muhs worked as the Chief Scientific Officer at AC Immune SA from 2005 to 2018.
Prior to that, he worked as the Director of Pharmacology & Histology at Cardion GmbH and as a Principal at ViaCell, Inc. Dr. Muhs holds a doctorate degree from Heinrich-Heine-Universität Düsseldorf.
Anciens postes connus de Andreas Muhs
| Sociétés | Poste | Fin |
|---|---|---|
| AC IMMUNE SA | Chief Tech/Sci/R&D Officer | 22/10/2018 |
Cardion GmbH
 Cardion GmbH Medical SpecialtiesHealth Technology Cardion GmbH develops biopharmaceutical products. It integrates synergistic local gene delivery stem cell engineering and tolerance induction capabilities to build cardiovascular gene therapy products. The company is headquartered in Dusseldorf, Germany. | Corporate Officer/Principal | - |
ViaCell, Inc.
 ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Formation de Andreas Muhs
| Heinrich-Heine-Universität Düsseldorf | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| AC IMMUNE SA | Health Technology |
| Entreprise privées | 2 |
|---|---|
ViaCell, Inc.
ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | Health Technology |
Cardion GmbH
Cardion GmbH Medical SpecialtiesHealth Technology Cardion GmbH develops biopharmaceutical products. It integrates synergistic local gene delivery stem cell engineering and tolerance induction capabilities to build cardiovascular gene therapy products. The company is headquartered in Dusseldorf, Germany. | Health Technology |
